Compare HKIT & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKIT | TXMD |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 25.9M |
| IPO Year | 2018 | 2012 |
| Metric | HKIT | TXMD |
|---|---|---|
| Price | $1.07 | $2.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.4K | 27.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.61 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $90.64 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.53 | $0.72 |
| 52 Week High | $4.21 | $2.95 |
| Indicator | HKIT | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 52.54 |
| Support Level | N/A | $1.05 |
| Resistance Level | $1.44 | $2.54 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 35.27 | 75.86 |
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.